Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study

dc.contributor.author	Cicero, Sherri
dc.contributor.author	Besisik, Sevgi
dc.contributor.author	Zhang, Lei
dc.contributor.author	Fu, Tommy
dc.contributor.author	Witzig, Thomas E.
dc.contributor.author	Williams, Michael E.
dc.contributor.author	Goy, Andre
dc.contributor.author	Sinha, Rajni
dc.contributor.author	Drach, Johannes W.
dc.contributor.author	Ramchandren, Rod
dc.date.accessioned	2021-03-03T20:34:06Z
dc.date.available	2021-03-03T20:34:06Z
dc.identifier.citation	Williams M. E. , Goy A., Sinha R., Besisik S., Drach J. W. , Ramchandren R., Zhang L., Cicero S., Fu T., Witzig T. E. , "Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study", 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
dc.identifier.other	vv_1032021
dc.identifier.other	av_5a968dfa-9276-4acd-b744-ab503e08e836
dc.identifier.uri	http://hdl.handle.net/20.500.12627/63651
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	31
dc.contributor.firstauthorID	141563

Files in this item

Files	Size	Format	View
There are no files associated with this item.